Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SAfiledCriticalRoussel Uclaf SA
Priority to FR870558ApriorityCriticalpatent/FR1485M/fr
Application grantedgrantedCritical
Publication of FR1485MpublicationCriticalpatent/FR1485M/fr
C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J75/00—Processes for the preparation of steroids in general
Landscapes
Chemical & Material Sciences
(AREA)
Organic Chemistry
(AREA)
Health & Medical Sciences
(AREA)
General Health & Medical Sciences
(AREA)
FR870558A1961-08-101961-08-10Nouveau médicament notamment pour le traitment de l'hyper cholésterolémie et des troubles en résultant.
ActiveFR1485M
(fr)
Nouveau médicament notamment pour le traitement de l'andropause, de la sénescence et des troubles de l'anabolisme protéique et de l'édification cellulaire.
Nouveau médicament notamment pour le traitement des manifestations de l'hyperémotivé, de l'anxiete et des troubles dus a l'hyperexcitabilité.
Nouveau médicament notamment pour le traitement des manifestations de l'hyperémotivite, de l'anxiété et des troubles dus a l'hyperexcitabilité.